marked.bio

HER2 ADC · ADC

ARX788

1 active trials across 2 of our biomarkers, targeting HER2. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 2 Phase 2
HER2 (ERBB2) activating mutation 0 2 –

Trials

1 of 4 trials shown

  1. ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

    Recruiting Phase 2 Laura Huppert, MD, BA Started 2026Primary completion 2029-11 NCT06224673

    ARX788Amiloride

    Pathologically documented HER2-low locally advanced unresectable or metastatic breast cancer (MBC).

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)HER2 Low Breast Carcinoma, Triple Negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma